Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fundamental and clinical studies on tobramycin (TOB) by intravenous drip infusion were carried out, and following results were observed. 1) Serum concentration of TOB. TOB was administered 1.5 mg/kg or 3.0 mg/kg by intramuscular or intravenous drip infusion method to 16 pediatric patients. In 1.5 mg/kg dose, the mean peak serum concentration were 3.9 mcg/ml at the 1/4 approximately 1/2 hour after administration by intramuscular method, 4.9 mcg/ml at the 1/2 hour after administration by 30 minutes intravenous drip infusion, 6.4 mcg/ml at 1 hour by 60 minutes intravenous drip infusion method. The half lives (T 1/2) of TOB in those methods, were 1.48, 1.42, 1.26 hours, respectively. In 3.0 mg/kg dose schedule by 30 or 60 minutes intravenous drip infusion method, the mean peak serum concentrations were 11.5 mcg/ml, 8.0 mcg/ml at the end of infusion, respectively. Those of the T 1/2 were 1.54, 1.24 hours. Pharmacokinetic parameters of TOB were following results. The ranges of Vd (apparent volume of distribution), K10 (elimination constant (hr-1)), T 1/2 were 0.20 approximately 0.34 L, 0.63 approximately 1.37 hr-1, 1.20 approximately 2.07 hrs., respectively and there was no significant difference in the serum concentrations and in the pharmacokinetic parameters. 2) Clinical results. Eight patients including 1 purulent cervical lymphadenitis, 4 acute pyelonephritis, 2 bronchopneumonia, 1 septicemia were treated with TOB 1.5 mg/kg or 3.0 mg/kg twice a day, by intravenous drip infusion for 6 approximately 15 days. Clinical effects were excellent in 3 cases, good in 4 cases and poor in 1 case. Efficacy rate was 87.5%. No side effects were observed.
 ...
PMID:[Fundamental and clinical studies on tobramycin by intravenous drip infusion (author's transl)]. 733 77